Covidien’s Ev3 logs a pair of legal wins over Appriva, whistleblower
Medtech legal news for the week of Mar. 17, 2014
Covidien’s ev3 seeks new trial in $175M loss to Appriva
Covidien’s got a ‘new approach’ to peripheral arterial disease
Jury hands Covidien’s ev3 subsidiary a possible $275M loss
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Mixed feelings for Covidien’s Pipeline embolization device following deaths
Layoffs: Covidien to shutter South Carolina plant, cutting 595 jobs
FDA warns on Covidien’s liquid embolic system following 9 patient deaths
Covidien touts FDA clearance for “game-changing” Solitaire revascularization device
Covidien plc (NYSE:COV) won FDA clearance for its Solitaire FR revascularization device for removing blood clots and restoring blood flow in the brains of patients suffering acute ischemic stroke.
The federal watchdog agency cleared the device, which physically removes blood clots from vessels, on the basis of data gathered during Covidien’s Swift study, the first of its kind to compare mechanical interventions for acute ischemic stroke, according to a press release.
